In its most recent SEC filing for the third quarter, Banyan Capital Management Inc. disclosed the acquisition of 3,853 shares of Johnson & Johnson, representing a new position valued at approximately $714,000. This allocation accounts for roughly 0.3% of Banyan’s overall portfolio, ranking J&J as its 22nd largest holding. The move marks Banyan’s first reported investment in the healthcare giant, signaling confidence in J&J’s diversified business mix across pharmaceuticals, medical devices and consumer health segments.

Several large investors adjusted their J&J exposure in the same period. Norges Bank initiated a stake worth $4.88 billion, while Laurel Wealth Advisors increased its share count by over 7.37 million shares—an uplift of more than 15,000%—to a total holding valued at $1.13 billion. Vanguard Group added 3.09 million shares (+1.3%), bringing its total to 237 million shares worth $36.2 billion, and Geode Capital Management expanded by 1.23 million shares (+2.1%) to 60.6 million shares valued at $9.23 billion. Legal & General Group increased its position by 1.1 million shares (+6.2%), now holding 18.9 million shares valued at $2.89 billion. Collectively, these moves underscore that institutional investors control 69.6% of J&J’s outstanding stock.

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on AKEEGA (niraparib plus abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer, clearing a key step toward broad label expansion in oncology. In the U.S., a federal judge dismissed a fraud lawsuit challenging J&J’s talc bankruptcy strategy, removing one potential liability overhang, although commentators warn that broader talc litigation continues. These regulatory and legal updates support incremental revenue upside in the pharmaceuticals division and alleviate short-term legal risk concerns.

Buy–side firms have grown more bullish following J&J’s solid quarterly results and strategic developments. Daiwa Capital Markets maintained its Outperform rating while raising its target to $237; Scotiabank lifted its target to $265 and reiterated Outperform; Morgan Stanley upgraded J&J, highlighting an enhanced growth outlook that underpins recent fresh annual highs. Royal Bank of Canada set a $240 target, Guggenheim raised its target from $227 to $240, and Citigroup increased its objective to $250 with a Buy rating. Of seventeen Buy ratings and eight Hold ratings, J&J’s consensus Moderate Buy rating and average target of $233.05 reflect sustained analyst confidence.